For all of you out there who have resolved to lose some weight, we will continue with this “know thy enemy” theme and talk once again about fat. Losing…
Beginning of the year notes….
At the risk of sounding unhumble, I’ve been doing pretty well with some of my big 2010 resolutions. We’re a little…
This is my go-to chili recipe for everything from Frito pies to chili fries. It can be left very basic or made more interesting with additions like chopped onions, kidney and pinto beans, and cans of diced tomatoes and chilies. But whatever the eventual use, I never make chili without adding a mixture of masa (used in Mexican cooking) and water.
A new analysis funded by Novo Nordisk's National Changing Diabetes® Program, found that the cost of diabetes and pre-diabetes reached $218 billion in 2007, with the exploding number of cases of type 2 diabetes responsible for the majority of the costs.
According to the study, diagnosed type 2 diabetes accounted for $174.4 billion of 2007...
People with diabetes of all ages, from all walks of life, are regularly reprimanded, shamed and degraded by healthcare professionals when they don't meet medical standards for normal blood glucose levels...
Today’s a big day for anyone with Type 1 diabetes: JDRF just announced a partnership with the Animas Corporation to develop what they’re…
The Juvenile Diabetes Research Foundation announced it had teamed up Animas Corporation to develop an automated system to help people with type 1 diabetes better control their disease - the first step on the path to what would be among the most revolutionary advancements in treating type 1 diabetes: the development of an artificial pancreas...
Novo Nordisk announced that it has initiated its first phase 1 clinical trial with a long-acting oral GLP-1 analogue (NN9924). The aim of the trial, which is conducted in the UK, is to investigate the safety, tolerability and bioavailability of NN9924 in healthy volunteers. Results from the trial, which is planned to enroll about 155 people, are expected to be reported in 2011...
MannKind Corp. announced that it was informed today by the FDA that they will not be able to complete the review of MannKind's new drug application for its ultra rapid-acting insulin therapy by the action date of January 16, 2010.The FDA explained that it has not yet completed its inspection of the insulin manufacturing facilities of N.V. Organon, a third-party supplier to MannKind....
Having diabetes makes me pay attention to all sorts of things that, in my previous life, I could have cared less about. Like, for example, the different…